Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Shirai (Shizuoka, Japan), K. Hirai (Shizuoka, Japan), Y. Gon (Tokyo, Japan), S. Maruoka (Tokyo, Japan), K. Mizumura (Tokyo, Japan), M. Hikichi (Tokyo, Japan), K. Itoh (Shizuoka, Japan), S. Hashimoto (Tokyo, Japan). Combined assessment of serum eosinophil-derived neurotoxin and YKL-40 may identify asthma-COPD overlap. 5040

Member's Comments

No comment yet.

Related content which might interest you: New genetic variants associated with eosinophil cationic protein and eosinophil-derived neurotoxin levels identified through bivariate genome-wide association study Source: International Congress 2019 – Genes and environment Year: 2019 Eosinophil-derived neurotoxin levels in serum are associated with asthma-like symptoms Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Point of care measurement of eosinophil derived neurotoxin (EDN) as a biomarker of eosinophilic asthma Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Characterisation of asthma subgroups associated with circulating YKL-40 levels Source: Eur Respir J, 50 (4) 1700800; 10.1183/13993003.00800-2017 Year: 2017 The relationship between the serum YKL-40 level and severity of asthma Source: Annual Congress 2012 - Asthma management Year: 2012 YKL-40 protein as a marker of asthma Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity. Source: International Congress 2017 – COPD biomarkers Year: 2017 Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 The association of C-reactive protein, serum amyloid-A and fibrinogen with prevalent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 506s Year: 2001 Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Analysis of IgE and C-reactive protein as possible predictors of exacerbation patients with asthma Source: Annual Congress 2011 - Biomarkers of allergic inflammation Year: 2011 Serum eosinophil cationic protein as a marker of disease severity in patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 51s Year: 2001 Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002 Visfatin as a possible serum biomarker in COPD Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases Year: 2019 Is there a relationship between severity of COPD and C-reactive protein (CRP) levels? Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006 Increased serum IL-17 does not predict future risk and impairment in asthma Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009 Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021